Influence of genetic co‐mutation on chemotherapeutic outcome in NPM1‐mutated and FLT3‐ITD wild‐type AML patients

Ähnliche Einträge

• Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3‐tyrosine kinase domain mutations: Prognostic implications of NPM1 co‐mutation
  von: Sankalp Arora, et al.
  Veröffentlicht: (2025)
• Clinical and genetic characteristics predict outcomes of acute myeloid leukemia patients with FLT3 mutations receiving venetoclax‐based therapy
  von: Guangyang Weng, et al.
  Veröffentlicht: (2024)
• Deep Sequencing of FLT3 ‐ITD Enables Response Evaluation and Post‐Treatment Monitoring in Childhood AML: An Exploratory Study
  von: Sofie Johansson Alm, et al.
  Veröffentlicht: (2026)
• Upfront intensive treatment analysis of the Italian Cohort Study on FLT3‐mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real‐life setting
  von: Jacopo Nanni, et al.
  Veröffentlicht: (2025)
• Dynamics of measurable residual disease for risk stratification and guiding allogeneic transplant in acute myeloid leukaemia patients with myelodysplasia‐related mutations in first remission
  von: Ling Jiang, et al.
  Veröffentlicht: (2024)